A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets

A multi-center, randomized, placebo-controlled, double-blinded (within cohorts), Sponsor-unblinded, Phase 1b study to explore the safety, pharmacokinetics, and pharmacodynamics of CX11 tablets in participants with obesity or overweight with weight-related comorbidities.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Obesity & Overweight Body Weight Nutrition Disorders Nutritional and Metabolic Diseases Obesity Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year–55 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 1

Primary location

Corxel Investigational site, Las Vegas, Nevada, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Male or female, 18-55 years.
BMI ≥30.0 to ≤39.9 kg/m², or ≥27.0 to <30.0 kg/m² with at least 1 weight-related comorbidity: prediabetes, hypertension, dyslipidemia, or obstructive sleep apnea.
Prior unsuccessful diet/exercise weight-loss attempt and stable body weight within 90 days.
Able to comply with study procedures and reproductive requirements.

Exclusion criteria

Diabetes or obesity due to endocrine/genetic causes.
Recent weight-loss drugs, GLP-1-based therapy, glucose-lowering drugs, obesity surgery/device, or investigational treatment.
Significant cardiovascular, ECG/QT, pancreatic, gallbladder, GI, liver, kidney, thyroid, psychiatric, malignant, infectious, autoimmune, or lab abnormality risks.
Personal/family history of medullary thyroid carcinoma or multiple endocrine neoplasia.
Pregnancy, breastfeeding, recent nicotine/drug use, excessive alcohol use, or any condition/medication making participation inappropriate.

Treatment and study plan

CX11

Drug

CX11 tablets administered orally once daily (QD) with meals

Placebo

Other

Matching placebo tablets administered orally once daily (QD) with meals

Primary outcomes

Percentage change in body weight from baseline

Time frame: Week 26

Study contacts

Contact information is provided by the study sponsor or research team.

Study coordinator

CONTACT

[email protected]

201-268-3723

Sponsors and collaborators

Lead sponsor

Corxel Pharmaceuticals

Industry

Registry information

Official study title

A Phase 1b Study Investigating Safety, Pharmacokinetics, and Pharmacodynamics of CX11 Tablets in Participants With Obesity or Overweight With Weight-Related Comorbidities

Important dates

Study start: 2026
Primary completion: 2027
Study completion: 2027
First posted: Jun 16, 2026
Registry last updated: Jun 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting